In the link below there is speculation on the potential role ruxolitinib, a JAK1 and JAK2 inhibitor may have played in an HIV BMT patient (the Geneva patient) who might be clear of the virus, as the donor cells did not have the delta 32 mutation. Alternate theory is that the GVHD did yeoman’s work in destroying infected cells and that makes equal sense to me.

Posting here mainly to solicit feedback from OHM that pertains to a strategy for definitive cure. We know Leronlimab will block viral entry into a cell that has not been infected but there are viral reservoirs that need to be flushed out of hiding…I recall drugs posited to potentially play a role here…would they share the same mechanism as ruxolitinib?

https://www.wired.com/story/a-patient-may-be-...detectable.